{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:40:00Z","timestamp":1756323600798,"version":"3.44.0"},"reference-count":38,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,11,24]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>A postmenopausal woman presented with a painful, erythematous rash affecting her head and neck. CT imaging revealed diffuse areas of skin thickening affecting her face and neck, and necrotic lymphadenopathy. Additional imaging revealed several osteolytic bone lesions. Biopsy reported a malignant vascular neoplasm, suggestive of angiosarcoma. Molecular analysis reported a <jats:italic>TRIM24::BRAF<\/jats:italic> gene fusion. After progression on first-line paclitaxel, the MEK inhibitor trametinib was administered, resulting in an excellent clinical and radiological response. This case reports a novel gene fusion, to our knowledge, the first reported in sarcoma, and highlights the utility and importance of molecular profiling in obtaining access to a treatment that may not otherwise be considered in standard site-specific therapeutic regimens, where therapeutic options may be limited.<\/jats:p>","DOI":"10.1136\/bcr-2024-261985","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T09:25:35Z","timestamp":1734859535000},"page":"e261985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced cutaneous angiosarcoma with a <i>TRIM24::BRAF<\/i> gene fusion treated with trametinib"],"prefix":"10.1136","volume":"17","author":[{"given":"Patrick","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada"},{"name":"Medical Oncology, Mount Sinai Hospital PLM, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Pankiw","sequence":"additional","affiliation":[{"name":"Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Gibbings","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mount Sinai Hospital PLM, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada"},{"name":"Medical Oncology, Mount Sinai Hospital PLM, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1962-7893","authenticated-orcid":false,"given":"Geoffrey","family":"Watson","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mount Sinai Hospital PLM, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"2025082712194594000_17.12.e261985.1","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.923933","article-title":"Histopathological Features of Deep Soft Tissue Epithelioid Angiosarcoma in the Lower Extremity: A Rare Case Report","volume":"21","author":"Nguyen Cuong","year":"2020","journal-title":"Am J Case Rep"},{"key":"2025082712194594000_17.12.e261985.2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdcr.2019.09.025","article-title":"Rapidly progressive and fatal case of extragenital cutaneous epithelioid angiosarcoma with visceral involvement","volume":"6","author":"Abbott","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2025082712194594000_17.12.e261985.3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7181\/acfs.2023.00409","article-title":"Current understanding of angiosarcoma: disease biology and evolving treatment","volume":"24","author":"Kim","year":"2023","journal-title":"Arch Craniofac Surg"},{"key":"2025082712194594000_17.12.e261985.4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.currproblcancer.2015.07.007","article-title":"Cutaneous angiosarcoma","volume":"39","author":"Dossett","year":"2015","journal-title":"Curr Probl Cancer"},{"key":"2025082712194594000_17.12.e261985.5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","volume":"11","author":"Young","year":"2010","journal-title":"J Angiosarcoma Lancet Oncol"},{"key":"2025082712194594000_17.12.e261985.6","unstructured":"Schulte B , Robinson SI , Alexiev BA , et al . Angiosarcoma."},{"key":"2025082712194594000_17.12.e261985.7","doi-asserted-by":"crossref","first-page":"154118","DOI":"10.1016\/j.prp.2022.154118","article-title":"Angiosarcoma of the visceral organs: A morphological, immunohistochemical, and C-MYC status analysis","volume":"238","author":"Zhang","year":"2022","journal-title":"Pathol Res Pract"},{"key":"2025082712194594000_17.12.e261985.8","unstructured":"Thway K . WHO classification of tumours editorial board. In: WHO Classification of Tumours Series. 3. International Agency for Research on Cancer, 2020."},{"key":"2025082712194594000_17.12.e261985.9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2867::AID-CNCR2820751212>3.0.CO;2-8"},{"key":"2025082712194594000_17.12.e261985.10","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199110000-00001"},{"key":"2025082712194594000_17.12.e261985.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr138"},{"key":"2025082712194594000_17.12.e261985.12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z"},{"key":"2025082712194594000_17.12.e261985.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm381"},{"key":"2025082712194594000_17.12.e261985.14","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1090168","article-title":"Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors","volume":"10","author":"Guan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025082712194594000_17.12.e261985.15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0025"},{"key":"2025082712194594000_17.12.e261985.16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21140"},{"key":"2025082712194594000_17.12.e261985.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"2025082712194594000_17.12.e261985.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.004"},{"key":"2025082712194594000_17.12.e261985.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3146"},{"key":"2025082712194594000_17.12.e261985.20","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"2025082712194594000_17.12.e261985.21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx707","article-title":"The European Society for Medical Oncology (ESMO) Precision Medicine Glossary","volume":"29","author":"Yates","year":"2018","journal-title":"Ann Oncol"},{"key":"2025082712194594000_17.12.e261985.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"2025082712194594000_17.12.e261985.23","doi-asserted-by":"crossref","unstructured":"Zhang Q , Fu Q , Bai X , et al . Molecular Profiling\u2013Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Front Oncol 2020;10. doi:10.3389\/fonc.2020.532403","DOI":"10.3389\/fonc.2020.532403"},{"key":"2025082712194594000_17.12.e261985.24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3820"},{"key":"2025082712194594000_17.12.e261985.25","first-page":"741","article-title":"Trametinib: A Targeted Therapy in Metastatic Melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"2025082712194594000_17.12.e261985.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0107"},{"key":"2025082712194594000_17.12.e261985.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1746"},{"key":"2025082712194594000_17.12.e261985.28","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1016\/j.cllc.2019.02.020","article-title":"A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib","volume":"20","author":"Zhu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025082712194594000_17.12.e261985.29","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00650","article-title":"Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy","volume":"7","author":"Heinrich","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025082712194594000_17.12.e261985.30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29825"},{"key":"2025082712194594000_17.12.e261985.31","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Res"},{"key":"2025082712194594000_17.12.e261985.32","first-page":"96","article-title":"The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"P T"},{"key":"2025082712194594000_17.12.e261985.33","doi-asserted-by":"publisher","DOI":"10.1097\/01243894-200601000-00004"},{"key":"2025082712194594000_17.12.e261985.34","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025082712194594000_17.12.e261985.35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145035","article-title":"Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"2025082712194594000_17.12.e261985.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"2025082712194594000_17.12.e261985.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88703-9","article-title":"Combined VEGFR and MAPK pathway inhibition in angiosarcoma","volume":"11","author":"Wagner","year":"2021","journal-title":"Sci Rep"},{"key":"2025082712194594000_17.12.e261985.38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25345"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-261985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:19:56Z","timestamp":1756322396000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-261985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,22]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bcr-2024-261985"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-261985","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}